Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared on X/Twitter:
“SaponiQx, an Agenus Inc. company revolutionizes access with sustainable, scalable supply of the vital QS-21 STIMULON; a key component in vaccines, including GSK Shingrix (protection > 9 years) and world’s first malaria vax Mosquirix“
For details click here.
Source: Jennifer Buell/Twitter